Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcellx, Inc. - Common Stock (NQ:ACLX)

65.60 -0.73 (-1.10%)
Streaming Delayed Price Updated: 1:05 PM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcellx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development ↗
These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better. 
Via InvestorPlace
News headline image
Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Johnson Controls International plc (NYSE: JCI) moved lower during Tuesday’s session following weak quarterly results. 
Via Benzinga
News headline image
Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say ↗
Friday, Arcellx Inc (NASDAQ: ACLX) announced new data from its Phase 1 expansion study of CART-ddBCMA, now known as anitocabtagene autoleucel (anito-cel) for relapsed and/or  
Via Benzinga
News headline image
Where Arcellx Stands With Analysts ↗
 
Via Benzinga
News headline image
Analyst Ratings for Arcellx ↗
 
Via Benzinga
News headline image
Why Arcellx (ACLX) Stock Is Nosediving ↗
Arcellx Inc (NASDAQ: ACLX) shares are trading lower by 8.50% to $32.76 Tuesday morning after the FDA on Monday put a clinical hold on the company's multiple myeloma phase 2 trial. 
Via Benzinga
News headline image
The Latest Analyst Ratings for Arcellx ↗
 
Via Benzinga
News headline image
Chart Of The Day: Arcellx - Reimagining Cell Therapy ↗
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. 
Via Talk Markets
News headline image
3 Biotech Stocks That Could Be Multibaggers in the Making ↗
Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments. 
Via InvestorPlace
News headline image
Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead ↗
The companies will work together on treatments for multiple myeloma and lymphomas. 
Via Investor's Business Daily
News headline image
Kite and Arcellx Announce Expansion in Strategic Partnership
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Why Is Blood Cancer Focused Arcellx Stock Trading Higher Today? ↗
Arcellx Inc (NASDAQ: ACLX) announced that new clinical data from its Phase 1 study of CART-ddBCMA in patients with relapsed or refra 
Via Benzinga
News headline image
Where Arcellx Stands With Analysts ↗
 
Via Benzinga
News headline image
What 5 Analyst Ratings Have To Say About Arcellx ↗
 
Via Benzinga
News headline image
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders. 
Via Benzinga
News headline image
Starbucks, Teleflex, Roku, Shopify And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks traded higher, with the Dow Jones gaining more than 350 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
7 Biotech Stocks to Get In Now Before Investors Catch On ↗
Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them. 
Via InvestorPlace
News headline image
Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs ↗
CAR T therapies have major advantages over traditional cancer drugs. Here are three of the best cancer drug stocks set to benefit from CAR T. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023 ↗
 
Via Benzinga
News headline image
Analysts Stay Bullish On Arcellx's CART-ddBCMA's Long-term Therapeutic Potential ↗
The FDA lifted the partial clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2 Clinical Program. 
Via Benzinga
News headline image
FDA Gives Green Signal To Arcellx's Stopped Blood Cancer Study ↗
The FDA lifted the partial clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death ↗
A patient died in Arcellx's multiple myeloma drug study. But the underlying factors are complex. 
Via Investor's Business Daily
News headline image
Arcellx's Lead Product Candidate Hit By FDA Clinical Hold For Multiple Myeloma, Stock Falls ↗
The FDA has put a clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2 clinical program for CART-ddBCMA investigational new drug for  
Via Benzinga
News headline image
Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740. 
Via Benzinga
News headline image
Why Cano Health Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket ↗
Gainers 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
It's time for another dive into the biggest pre-market stock movers as we check out all the latest news for Tuesday morning! 
Via InvestorPlace
News headline image
Alibaba, Arcellx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023 ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2023 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.